<DOC>
	<DOCNO>NCT02305316</DOCNO>
	<brief_summary>Single-centre , open-label , randomised , two-way crossover study 28 healthy volunteer . The study consist two consecutive single-dose treatment period separate washout period 14 day .</brief_summary>
	<brief_title>Single-dose Pharmacokinetics Relative Bioavailability Two Different Formulations Opicapone</brief_title>
	<detailed_description>Single-centre , open-label , randomised , two-way crossover study 28 healthy volunteer . The study consist two consecutive single-dose treatment period separate washout period 14 day . A total twenty-eight ( 28 ) healthy volunteer receive single dose 50 mg OPC , orally .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<criteria>A sign date informed consent form ( ICF ) studyspecific screen procedure perform , Male female subject age 18 45 year , inclusive , Body mass index ( BMI ) 19 30 kg/m2 , Healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination 12lead electrocardiogram ( ECG ) , Negative test hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) antibodies antihuman immunodeficiency virus ( HIV ) antibodies screen , Clinical laboratory test result clinically acceptable screen D1 treatment period , Negative screen alcohol drug abuse screen D1 treatment period , Nonsmokers exsmokers least 3 month , Volunteer able participate , willing give write informed consent comply study restriction , If female : Was childbearing potential reason surgery , childbearing potential , use effective nonhormonal method contraception ( intrauterine device intrauterine system ; condom occlusive cap [ diaphragm cervical vault cap ] spermicidal foam gel film cream suppository ; true abstinence ; vasectomize male partner , provide sole partner subject ) entire duration study , Negative serum pregnancy test screen negative urine pregnancy test D1 treatment period . Any clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder , clinically relevant surgical history , Any clinically relevant abnormality coagulation test , Any clinically relevant abnormality liver function test , History relevant atopy drug hypersensitivity , History alcoholism and/or drug abuse , Current consumption 14 unit alcohol per week [ 1 unit alcohol = 280 mL beer ( 34° ) = 100 mL wine ( 1012° ) = 30 mL spirit ( 40° ) ] , Any significant infection know inflammatory process screen admission treatment period , Any acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhoea , heartburn ) time screen admission treatment period , Use medicine within 2 week admission first period could affect subject 's safety study assessment , investigator 's opinion , Previously receive opicapone , Involvement clinical trial type within 90 day prior screen , Participation 2 clinical trial within 12 month prior screen , Blood donation receive blood transfusion blood product within 3 month prior screen , Vegetarian , vegan medical dietary restriction , Subject able communicate reliably investigator , Subjects unlikely cooperate requirement study , Subjects unwilling unable give write informed consent , If female : Pregnant breastfeeding , If childbearing potential , positive serum pregnancy test , Volunteer use accept effective contraceptive method use oral contraceptive ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>